Evidence map›Paper›PMID 38980909›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Esmerina Tili, Hajime Otsu, Teresa L Commisso, Alexey Palamarchuk, Veronica Balatti, Jean-Jacques Michaille, Gerard James Nuovo, Carlo M Croce

Erratum issuedAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Loss of ICOSL expression in the progression to cervical carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Nasopharyngeal carcinoma: a model cancer to understand tumor rejection.Signal transduction and targeted therapy · 2025
    Article
  9. Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Esmerina Tili *Department of Anesthesiology, Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, OH 43210.
Hajime Otsu *The Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.
Teresa L CommissoThe Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.
Alexey PalamarchukThe Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.
Veronica BalattiThe Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.
Jean-Jacques MichailleThe Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.
Gerard James NuovoGNOME, Inc., Powell, OH 43065.
Carlo M CroceThe Ohio State University, Comprehensive Cancer Center, Department of Cancer Biology and Genetics, Wexner Medical Center, Columbus, OH 43210.ORCID 0000-0003-3788-1457

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
CLL Global Research Foundation (CLLGRF) AWD-115284CLL Global Research Foundation (CLLGRF) AWD-116510HHS | NIH | National Cancer Institute (NCI) P30CA016058NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Elevated levels of

Indexed as

Inducible T-Cell Co-Stimulator LigandMicroRNAsAnimalsB-LymphocytesCell Line, TumorGene Expression Regulation, NeoplasticHumansInducible T-Cell Co-Stimulator ProteinMiceMice, Inbred C57BLNeoplasmsT-Lymphocytes, CytotoxicIcosl protein, mouseInducible T-Cell Co-Stimulator LigandInducible T-Cell Co-Stimulator ProteinMicroRNAsMirn155 microRNA, mouseimmune rejectionimmune therapylymphomamicroRNA targetingsolid tumor

Identifiers

PMID38980909
PMCPMC11260163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.